Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial
Titel:
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial
Auteur:
Pu, Xingxiang Xiao, Zemin Li, Jia Wu, Zhijun Ma, Zhongxia Weng, Jie Xiao, Maoliang Chen, Yanhua Cao, Yongqing Cao, Peiguo Wang, Qianzhi Xu, Yan Li, Kang Chen, Bolin Xu, Fang Liu, Liyu Kong, Yi Zhang, Hui Duan, Huaxin Wu, Lin